Search research articles
Contact Us
Filters
Showing results (541-550 of 566) with videos related to
Page
of 57
Sort By:
Clinica Chimica Acta; International Journal of Clinical Chemistry
|
May 31, 2011
Combining body mass index and serum potassium to urine potassium clearance ratio is an alternative method to predict primary aldosteronism
Chin-Chi Kuo, Vin-Cent Wu, Ching-Wei Tsai, et al.
The Lancet. Gastroenterology & Hepatology
|
February 6, 2025
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial
Young-Suk Lim, Ming-Lung Yu, Jonggi Choi, et al.
The New England Journal of Medicine
|
January 8, 2025
Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B
Jinlin Hou, Wenhong Zhang, Qing Xie, et al.
Clinical and Molecular Hepatology
|
July 13, 2021
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
September 17, 2016
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
Tung-Hung Su, Tsung-Hui Hu, Chi-Yi Chen, et al.
Gut
|
January 7, 2021
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Hepatology International
|
March 7, 2021
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
Chen-Hua Liu, Po-Yueh Chen, Jyh-Jou Chen, et al.
Hepatology International
|
January 26, 2023
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan
Chen-Hua Liu, Cheng-Yuan Peng, Chun-Jen Liu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 22, 2025
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study
Teng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Clinical and Molecular Hepatology
|
February 5, 2025
Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study
Shou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Page
of 57
Search research articles
Search
Showing results (541-550 of 566) with videos related to
Sort By:
Page
of 57
Clinica Chimica Acta; International Journal of Clinical Chemistry
|
May 31, 2011
Combining body mass index and serum potassium to urine potassium clearance ratio is an alternative method to predict primary aldosteronism
Chin-Chi Kuo, Vin-Cent Wu, Ching-Wei Tsai, et al.
The Lancet. Gastroenterology & Hepatology
|
February 6, 2025
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial
Young-Suk Lim, Ming-Lung Yu, Jonggi Choi, et al.
The New England Journal of Medicine
|
January 8, 2025
Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B
Jinlin Hou, Wenhong Zhang, Qing Xie, et al.
Clinical and Molecular Hepatology
|
July 13, 2021
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
September 17, 2016
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
Tung-Hung Su, Tsung-Hui Hu, Chi-Yi Chen, et al.
Gut
|
January 7, 2021
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Hepatology International
|
March 7, 2021
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
Chen-Hua Liu, Po-Yueh Chen, Jyh-Jou Chen, et al.
Hepatology International
|
January 26, 2023
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan
Chen-Hua Liu, Cheng-Yuan Peng, Chun-Jen Liu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 22, 2025
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study
Teng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Clinical and Molecular Hepatology
|
February 5, 2025
Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study
Shou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Page
of 57